Gilead Sciences Inc.

(NASDAQ: GILD) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Contact Information

Website: www.gilead.com
Email: investor_relations@gilead.com
Main Phone: +1 650 574-3000
Address: 333 Lakeside Drive
State: CA
City / Town: Foster City
Country: US
Postal Code: 94404

Issuer Information

Exchange: NGS
CEO: Daniel O'Day
Employees: 11800
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A